BRIEF-Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)

Longeveron

Longeveron

LGVN

0.00

May 11 (Reuters) - Longeveron Inc LGVN.O:

  • LONGEVERON ANNOUNCES INDEPENDENT DATA MONITORING COMMITTEE POSITIVE REVIEW AND RECOMMENDATION TO COMPLETE PHASE 2B STEM CELL THERAPY CLINICAL TRIAL IN HYPOPLASTIC LEFT HEART SYNDROME (HLHS)

  • LONGEVERON INC - DMC FINDS NO SAFETY CONCERNS, RECOMMENDS PHASE 2B TRIAL CONTINUE TO COMPLETION

  • LONGEVERON INC - TOP-LINE RESULTS FROM ELPIS II TRIAL ANTICIPATED IN AUGUST 2026

Source text: ID:nGNXZJ6w7

Further company coverage: LGVN.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.